ICON Partners with Korea National Enterprise for Clinical Trials
ICON plc
, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and
Korea National Enterprise for Clinical Trials
(KoNECT) today announced they have signed a partnership agreement that aims to advance the clinical trials industry in South Korea.
Through the agreement, ICON and KoNECT will collaborate on a series of educational events for local and multinational pharmaceutical companies, investigators and industry officials. The programmes aim to further enhance the already high standards of clinical research in South Korea and will kick off with an oncology trials seminar in Seoul on October 26th.
“South Korea has become a key country for clinical development and ICON has had a well-established presence there since 2005,” commented Wei Ming Goh, ICON’s Vice President, Asia-Pacific. “Our agreement with KoNECT supports our mutual interest in developing and growing the clinical research industry in South Korea and demonstrates our on-going commitment to the Asia Pacific region.”
KoNECT President, Professor Sang-Goo Shin, added, “We are delighted to collaborate with a leading clinical research organisation such as ICON that has a wealth of expertise in both local and global clinical development programmes. Together we can develop high quality clinical research professionals and a clinical trials infrastructure that can support the increased demand from local and global pharma companies.”
ICON is one of the leading CROs in Asia-Pacific, employing over 1,400 staff in the region from locations in 13 countries. Learn more about ICON’s capabilities in Asia-Pacific at
http://www.iconplc.com/emerging-markets/
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
